Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 42.46% | 28.46% | 42.11% | 20.02% | 48.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.46% | 28.46% | 42.11% | 20.02% | 48.04% |
| Cost of Revenue | -14.39% | -10.60% | -1.42% | 11.03% | 15.30% |
| Gross Profit | 125.78% | 80.23% | 103.08% | 35.41% | 153.57% |
| SG&A Expenses | 8.85% | 9.82% | 0.65% | -7.52% | -5.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.29% | 0.21% | -0.27% | 0.30% | 3.65% |
| Operating Income | 188.73% | 133.60% | 136.00% | 39.30% | 53.92% |
| Income Before Tax | 160.78% | 112.26% | 118.84% | 31.56% | 46.46% |
| Income Tax Expenses | 40.81% | 48.19% | -26.27% | -13.14% | -34.01% |
| Earnings from Continuing Operations | 159.58% | 111.31% | 117.99% | 31.46% | 46.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 159.58% | 111.31% | 117.99% | 31.46% | 46.39% |
| EBIT | 188.73% | 133.60% | 136.00% | 39.30% | 53.92% |
| EBITDA | 190.35% | 134.92% | 137.06% | 39.52% | 54.16% |
| EPS Basic | 158.69% | 110.72% | 116.93% | 33.45% | 48.16% |
| Normalized Basic EPS | 160.41% | 111.76% | 117.89% | 33.17% | 48.68% |
| EPS Diluted | 155.22% | 106.69% | 114.90% | 33.27% | 48.02% |
| Normalized Diluted EPS | 157.46% | 108.71% | 115.49% | 33.17% | 48.68% |
| Average Basic Shares Outstanding | 1.74% | 1.80% | 2.05% | 2.43% | 2.96% |
| Average Diluted Shares Outstanding | 3.22% | 2.54% | 2.79% | 2.43% | 2.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |